Business Wire
-
Bruker Introduces The Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System For Drug Discovery At SLAS2024
2/5/2024
At the SLAS2024 International Conference and Exhibition, Bruker Corporation today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
-
SCIEX Expands High-Throughput Screening Solutions With Echo MS+ System
2/2/2024
SCIEX, a global leader in life science analytical technologies, launches the Echo MS+ system at SLAS 2024.
-
Inoviv Secures Investment To Expand Quantitative Proteomics Product Offerings To Accelerate Drug Development Pipelines
1/30/2024
Biomarker pioneer Inoviv has secured significant funding from venture capital firm Hoxton Ventures and leading investment manager Foresight Group to expand the delivery of highly accurate, fully quantitative targeted biomarker workflows and panels.
-
Opentrons Launches Automation Marketplace To Expand Lab Robotics Accessibility And Streamline Drug Discovery And Microbiome Research
1/30/2024
Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its automation marketplace, with tools and software from Opentrons’ partners that can be easily integrated into Opentrons robotics systems, catering to rapidly expanding sectors like drug discovery and microbiome research.
-
Variational AI Announces Generative AI Project With Merck
1/25/2024
Variational AI, developer of the Enki generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research Labs supported by the CQDM Quantum Leap program.
-
Juvena Therapeutics Receives FDA Orphan Drug Designation For JUV-161 For The Treatment Of Myotonic Dystrophy Type 1
1/23/2024
Juvena Therapeutics, a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominant inherited disease and the most common form of adult muscular dystrophy.
-
Chemify Partners With Prepaire Labs To Apply Ground-Breaking Chemistry AI-Robotics To Radically Accelerate The Discovery Of Non-Addictive Opioids
1/18/2024
Chemify and Prepaire Labs today announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform.
-
Neuraptive Therapeutics Inc. Receives Orphan Drug Designation For Its Lead Development Asset
1/15/2024
Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the United States (US) Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit.
-
Debiopharm And ThinkingNodeLife.ai Forge A Strategic Partnership To Propel Cancer Drug Development With AI Digital Cell Clones
1/10/2024
Debiopharm, an independent biopharmaceutical company headquartered in Switzerland, and ThinkingNodeLife.ai (TNL), a trailblazer in AI Digital Cells Lab in USA, are pleased to announce a collaborative partnership aimed at advancing the development of a cutting-edge cancer drug.
-
Bifrost Biosystems Launches With Novel Optical Pooled Screening Technology To Power Efficient Discovery
1/9/2024
Bifrost Biosystems announced today its launch with a vision to power efficient drug discovery through its novel automated Optical Pooled Screening (OPS) platform.